Bluesky Facebook Reddit Email

PPAR-g agonists have potential therapeutic role in gastric carcinoma?

08.26.09 | World Journal of Gastroenterology

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied. However, the potential therapeutic role of PPAR-γ agonists has been questioned, based on contradictory results. Studies using animal models of colon cancer found that PPAR-γ agonists increased the development of colon tumors. This contradictory result was supplemented by a recent report using transgenic mice expressing a constitutive active form of PPAR-γ in mammary glands which showed that PPAR-γ signaling accelerated tumor development in mammary glands. The actual role of PPAR-γ in cancer has been complicated by recent findings that PPAR-γ agonists affect cancer cells independently of PPAR-γ, and silencing of PPAR-γ and a PPAR-γ antagonist inhibit cancer cell growth. To date, the role of PPAR-γ in gastric carcinogenesis remains unclear.

A research article to be published on August 21, 2009 in the World Journal of Gastroenterology addresses this question. A study from China found that PPAR-γ may be involved in gastric carcinogenesis, and that the PPAR-γ agonist 15d-PGJ2 may inhibit the growth of human gastric carcinoma MGC803 cell by inducing apoptosis and G1/G0 arrest, involving survivin, Skp2 and p27, but via a PPAR-γ-independent pathway.

The study showed that the PPAR-γ agonist 15d-PGJ2 inhibited growth of cultured gastric cancer MGC803 cells, and demonstrated that the PPAR-γ antagonist GW9662 did not block this effect of 15d-PGJ2 and that 2.5 μM GW9662 inhibited growth of MGC803 cells. Furthermore, PPAR-γ siRNA remarkably inhibited the growth of MGC803 cells.

These results indicated that 15d-PGJ2 inhibited growth of cultured gastric carcinoma MGC803 cells by a PPAR-γ-independent pathway. These results also suggest that PPAR-γ agonists could be useful in the chemoprevention or chemotherapy of gastric malignancies.

Reference: Ma XM, Yu H, Huai N. Peroxisome proliferator-activated receptor-g is essential in the pathogenesis of gastric carcinoma. World J Gastroenterol 2009; 15(31): 3874-3883

http://www.wjgnet.com/1007-9327/15/3874.asp

Correspondence to: Xiu-Mei Ma, Professor, MD, Department of Pathology, The First Affiliated Hospital of Inner Mongolia Medical College, Huhhot 010059, Inner Mongolia Autonomous Region, China. maxiumei0471@yahoo.com.cn

Telephone: +86-471-6637678

World Journal of Gastroenterology

Keywords

Article Information

Contact Information

How to Cite This Article

APA:
World Journal of Gastroenterology. (2009, August 26). PPAR-g agonists have potential therapeutic role in gastric carcinoma?. Brightsurf News. https://www.brightsurf.com/news/1GNZD0JL/ppar-g-agonists-have-potential-therapeutic-role-in-gastric-carcinoma.html
MLA:
"PPAR-g agonists have potential therapeutic role in gastric carcinoma?." Brightsurf News, Aug. 26 2009, https://www.brightsurf.com/news/1GNZD0JL/ppar-g-agonists-have-potential-therapeutic-role-in-gastric-carcinoma.html.